Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chemoimmunotherapy With Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in Children, Adolescents and Young Adults With Recurrent Refractory CD20+ Mature B-NHL

NCT02393157 is registered in ClinicalTrials.gov with New York Medical College as lead sponsor.

NCT NCT02393157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02393157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chemoimmunotherapy With Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in Children, Adolescents and Young Adults With Recurrent Refractory CD20+ Mature B-NHL
Lead sponsor
New York Medical College
Phase
Phase 2
Overall status
Recruiting
Start date
August 21, 2015
Completion date
December 31, 2027
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

burkitt lymphoma, cd20+ lymphoblastic lymphoma, diffuse large b-cell lymphoma, follicular lymphoma, grade iii, non-hodgkin lymphoma, primary mediastinal b-cell lymphoma